Skip to Main Content
Table 1—

Clinical characteristics of subjects

Healthy control subjectsType 2 diabetic subjects
PFNPLN
Sex (male/female) 5/10 5/5 6/6 
Age (years) 54.4 ± 9.7 61.0 ± 11.2 62.9 ± 10.2 
Duration (years) — 12.1 ± 4.2 13.3 ± 4.29 
BMI (kg/m225.4 ± 2.4 30.7 ± 3.1 32.3 ± 2.8 
A1C (%) — 8.2 ± 3.8 8.6 ± 3.5 
ABPI 1.1 ± 0.1 1.0 ± 0.2 1.2 ± 0.1 
VPT 7.08 ± 2.8 8.6 ± 2.2 37.1 ± 12.9 
VAS (0–10) 5.7 ± 1.1 
Healthy control subjectsType 2 diabetic subjects
PFNPLN
Sex (male/female) 5/10 5/5 6/6 
Age (years) 54.4 ± 9.7 61.0 ± 11.2 62.9 ± 10.2 
Duration (years) — 12.1 ± 4.2 13.3 ± 4.29 
BMI (kg/m225.4 ± 2.4 30.7 ± 3.1 32.3 ± 2.8 
A1C (%) — 8.2 ± 3.8 8.6 ± 3.5 
ABPI 1.1 ± 0.1 1.0 ± 0.2 1.2 ± 0.1 
VPT 7.08 ± 2.8 8.6 ± 2.2 37.1 ± 12.9 
VAS (0–10) 5.7 ± 1.1 

Data are means ± SD. There were no significant differences in age between the healthy control, PFN, and PLN groups. BMI was lower in the control subjects than in the PFN and PLN groups (P = 0.001 and P = 0.0001, respectively). Duration of diabetes and A1C were not significantly different between the PFN and PLN groups. ABPI was not different among the three groups. VPT was not significantly different between the healthy control and PFN groups but high in the PLN group (P < 0.0001). Visual analog scale (VAS) was high in the PFN group.

Close Modal

or Create an Account

Close Modal
Close Modal